VaxInnate keeps slowly raising capital for seasonal flu vaccine
VaxInnate, a New Jersey startup, has raised more equity - on top of $53 million in government contracts - to develop a seasonal and pandemic flu vaccine.
Well-capitalized VaxInnate gets another $6M for its bacteria-based flu vaccines
New Jersey’s VaxInnate is developing inoculations to ward off seasonal and pandemic flu, dengue fever and Clostridium difficile. The well-capitalized company has raised a recent round of $6 million, according to a regulatory filing. The company genetically fuses vaccine antigens to flagellin, a protein that forms the flagella of a bacterium that’s known for being highly […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Former head of Sanofi vaccines division becomes infectious disease biotech CEO
The former head of Sanofi’s (NYSE:SNY) vaccines division, one of the largest vaccine companies in the world, has joined a biotechnology company developing infectious disease vaccines as its CEO. Wayne Pisano will lead Cranbury, New Jersey-based VaxInnate, a biotechnology company founded by two Yale School of Medicine immunobiology professors in 2002 — Ruslan Medzhitov and […]